Skip to main content

Idexx Laboratories statistics

  • IDXX · Nasdaq
  • Biotechnology
  • Health Care Equipment
  • S&P 500
$704.23+0.89%Close 13 Nov 2026 · Market value $55.66B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Idexx Laboratories is valued at $55.66B on its latest close. Its price is 47.1 times its earnings.

Market value$55.66B
Enterprise value$55.79B
Price / earnings47.08
Price / sales11.94
Price / book29.78
EV / EBITDA33.52
EV / sales11.97
Price / free cash flow42.69
Price / free cash flow, own 5-year average59.81
EV / EBIT37.16
EV / free cash flow42.92
Free cash flow yield2.3%

Share price

Latest close$704.23
Day's change+0.9%
52-week high$769.98
52-week low$500.61
From 52-week high−8.5%
Return · 1 month+25.7%
Return · 3 months+29.0%
Return · year to date+4.1%
Return · 1 year−1.3%
Beta · 1 year against the S&P 5000.82
50-day average$562.41
200-day average$572.35
RSI 1471.6
Average volume · 20 sessions684K

Margins and returns

For fiscal 2025, as filed.

Gross margin61.8%
Operating margin31.6%
Net margin24.6%
Free cash flow margin24.6%
Return on equity66.2%
Return on assets32.8%
Return on invested capital50.4%
Return on invested capital, 5-year average46.9%
Return on capital employed61.4%
Stock-based compensation / revenue1.4%

Financial position

At the end of fiscal 2025.

Cash and equivalents$180.1M
Total debt$578.1M
Net debt$398.0M
Current ratio1.23
Quick ratio0.64
Debt / equity0.36
Net debt / EBITDA0.26
Interest coverage35.01

Growth

Revenue, latest quarter on a year+9.9%
Revenue, twelve months on a year+11.9%
EPS, latest quarter on a year+17.9%
EPS, twelve months on a year+17.6%
Revenue, 5-year compound+9.7%
Revenue, 10-year compound+10.4%
Net income, 5-year compound+12.7%
Free cash flow, 5-year compound+14.3%
EPS, 5-year compound+14.3%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares81.0M
Shares outstanding, 5-year compound−1.3%
Net share repurchases$1.12B

Taxes

For fiscal 2025, as filed.

Income tax expense$264.7M
Effective tax rate20.0%

IDXX in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.